Know Cancer

or
forgot password

IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study


Phase 1/Phase 2
18 Years
65 Years
Open (Enrolling)
Both
Nasopharyngeal Carcinoma

Thank you

Trial Information

IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study


Inclusion Criteria:



- Pathologically confirmed untreated NPC patients

- locoregionally advanced (T3-4 or N2-3 M0)

- 18-65 years

- with MRI examinations

- ECOG ≤ 2

- With written consent

Exclusion Criteria:

- Without a second cancer

- Pregnancy

- With other severe diseases (blood,liver ,kidney or heart diseases)

- Could not be staged properly

- Without written consent

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants with Adverse Events as a Measure of Safety

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Xia He, M.D. Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jiangsu Cancer Institute & Hospital

Authority:

China: Ethics Committee

Study ID:

LA-chemoR-c225

NCT ID:

NCT01712919

Start Date:

May 2010

Completion Date:

May 2013

Related Keywords:

  • Nasopharyngeal Carcinoma
  • Locoregionally advanced nasopharyngeal carcinoma
  • cetuximab
  • chemoradiation
  • Carcinoma
  • Nasopharyngeal Neoplasms

Name

Location